Trevena (NASDAQ:TRVN – Get Free Report) will likely be issuing its resultson Thursday, November 5th. Analysts expect Trevena to announce earnings of ($50.00) per share and revenue of $0.78 million for the quarter.
Trevena Stock Performance
Shares of NASDAQ TRVN opened at $0.01 on Thursday. Trevena has a 1 year low of $0.00 and a 1 year high of $1.50. The firm has a market cap of $10,644.90, a price-to-earnings ratio of -0.00 and a beta of -1.99. The stock’s 50-day simple moving average is $0.01 and its 200-day simple moving average is $0.01.
Trevena Company Profile
Trevena, Inc is a biopharmaceutical company focused on developing medicines for central nervous system disorders, with an emphasis on addressing the limitations of existing opioid and other neurological therapies. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an intravenous opioid approved by the U.S. Food and Drug Administration for the management of acute pain in adults severe enough to require an intravenous opioid analgesic.
Recommended Stories
- Five stocks we like better than Trevena
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
